Roger Rooswinkel
Direktor/Vorstandsmitglied bei Pheon Therapeutics Ltd.
Profil
Roger Rooswinkel is currently a Director at Pheon Therapeutics Ltd.
He previously worked as a Non-Executive Director at Achilles Therapeutics Plc.
Aktive Positionen von Roger Rooswinkel
Unternehmen | Position | Beginn |
---|---|---|
Pheon Therapeutics Ltd.
Pheon Therapeutics Ltd. BiotechnologyHealth Technology Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Roger Rooswinkel
Unternehmen | Position | Ende |
---|---|---|
ACHILLES THERAPEUTICS PLC | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ACHILLES THERAPEUTICS PLC | Health Technology |
Private Unternehmen | 1 |
---|---|
Pheon Therapeutics Ltd.
Pheon Therapeutics Ltd. BiotechnologyHealth Technology Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023. | Health Technology |